Conference Call Q1 2022 Results

Joachim Kreuzburg, Rainer Lehmann

Sartorius | Sartorius Stedim Biotech | April 21, 2022

Disclaimer

This presentation contains statements concerning the future performance of the Sartorius and the Sartorius Stedim Biotech Groups. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize.

This is because our assumptions harbor risks and uncertainties that could lead to actual results substantially diverging from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

Highlights

  • Dynamic start to the year with double-digit growth in sales and earnings in both divisions

  • Healthy demand situation; normalization of corona-related effects and order intake development as expected

  • Increase of profitability despite FX headwinds and higher costs for logistics and materials

  • Capacity expansion on schedule; successful closing of two acquisitions

  • 2022 forecast confirmed; global political and economic uncertainties substantially increased

Sartorius Group

Strong organic growth; further margin increase

Sartorius Group

Q1 2021

Q1 2022

in %

in % cc1

in millions of € unless otherwise specified

Sales revenue

791.1

1,024.8

+29.5

+25.4

Order intake

1,138.6

1,112.2

-2.3

-5.8

Underlying EBITDA2

263.5

349.0

+32.4

Underlying EBITDA2 margin in %

33.3

34.1

+0.8pp

Underlying EPS3 (ord.) in €

1.77

2.44

+37.6

Underlying EPS3 (pref.) in €

1.78

2.45

+37.3

  • Acquisitions contribute close to 2pp to sales growth

  • OI is normalizing as expected; prior-year figure impacted by pandemic and changed ordering patterns by some customers

  • Underlying EBITDA margin increased despite FX headwinds and higher costs for logistics and materials

1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Sartorius AG published this content on 21 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 April 2022 12:34:11 UTC.